Company intelligence / Profile preview
Carina Biotech
Adelaide, South Australia, Australiacarinabiotech.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
Lead candidate CNA3103 targeting LGR5 is in Phase 1/2a clinical trials for metastatic colorectal cancer with early promising clinical results. The trial is designed to enroll up to 44 patients with metastatic disease who have failed prior lines of chemotherapy and express LGR5 on their cancer cells.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyAdoptive cell therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Biosceptre (sold IP rights to first lead CAR-T cell)
Beyond the preview
Go deeper on Carina Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carina Biotech.